Workflow
四环生物(000518) - 2023 Q1 - 季度财报
JSSHJSSH(SZ:000518)2023-04-28 16:00

Financial Performance - The company's revenue for Q1 2023 was ¥57,013,482.58, representing a 13.22% increase compared to ¥50,357,114.91 in the same period last year[5] - The net loss attributable to shareholders was ¥18,959,108.45, an improvement of 18.55% from a loss of ¥23,275,808.58 in the previous year[5] - The company's basic and diluted earnings per share were both -¥0.0184, showing an improvement of 18.58% from -¥0.0226 in the same period last year[5] - Operating profit for Q1 2023 was -¥21,889,366.63, an improvement from -¥25,909,904.09 in Q1 2022[17] - Net profit for Q1 2023 was -¥21,122,207.95, compared to -¥25,909,848.63 in Q1 2022, showing a reduction in losses[18] - Total comprehensive income for Q1 2023 was -¥21,122,207.95, an improvement from -¥25,909,848.63 in Q1 2022[18] Cash Flow - The net cash flow from operating activities was ¥3,050,580.73, a significant increase of 141.37% compared to a negative cash flow of ¥7,374,282.57 in the same period last year[5] - Cash flow from operating activities for Q1 2023 was ¥3,050,580.73, a significant recovery from -¥7,374,282.57 in Q1 2022[20] - Cash flow from investing activities was -¥200,800.00 in Q1 2023, compared to -¥1,779,000.00 in Q1 2022, indicating reduced investment outflows[20] - Cash flow from financing activities was -¥5,374,002.44 in Q1 2023, worsening from -¥387,375.01 in Q1 2022[20] - The beginning cash and cash equivalents balance was ¥27,680,469.82, compared to ¥37,862,389.45 in the previous period, indicating a decrease of approximately 26.8%[21] - The ending cash and cash equivalents balance was ¥25,137,867.09, down from ¥28,308,162.95, reflecting a decline of about 11.4%[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥712,877,322.62, down 3.41% from ¥738,078,462.55 at the end of the previous year[5] - Total liabilities decreased to CNY 140,504,176.84 from CNY 144,583,108.82, representing a reduction of about 2.4%[14] - The company's cash and cash equivalents were CNY 25,637,530.70, down from CNY 28,180,123.46, indicating a decrease of approximately 9.2%[13] - Accounts receivable decreased to CNY 77,066,984.91 from CNY 100,116,017.59, a decline of about 23%[13] - Inventory increased slightly to CNY 410,622,090.87 from CNY 408,764,642.59, showing a marginal increase of approximately 0.4%[13] - The total equity attributable to shareholders decreased by 3.40% to ¥538,281,742.59 from ¥557,240,851.04 at the end of the previous year[5] - The company reported a total current liability of CNY 112,061,767.39, down from CNY 116,217,258.18, reflecting a decrease of approximately 3.6%[14] - The non-current assets totaled CNY 168,308,257.58, down from CNY 173,258,603.92, indicating a decrease of about 2.9%[13] Expenses and Subsidies - Research and development expenses decreased by 47.31% to ¥7,340,182.16 from ¥13,931,832.09 in the previous year[9] - The company received government subsidies amounting to ¥529,552.89, a significant increase of 17,826.21% compared to ¥2,954.07 in the previous year[9] - The company reported a 234.32% increase in taxes and additional fees paid, totaling ¥4,199,170.56 compared to ¥1,256,046.80 in the previous year[9] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 102,347, with the top two shareholders holding 28.32% of the total shares[10] - The company has no outstanding preferred shares or perpetual bonds as of the reporting date[14] - The company’s retained earnings showed a negative balance of CNY -565,581,208.49, worsening from CNY -546,622,100.04 at the beginning of the year[14] Audit Status - The first quarter report was not audited, indicating that the financial data may be subject to further review[22]